Metabolic Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Metabolic Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Metabolic Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Diabetic Retinopathy - Drugs In Development, 2024 Diabetic Retinopathy - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings in the vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. The Diabetic Retinopathy drugs in development market research report provide comprehensive information on...
-
Product Insights
Diabetic Macular Edema - Drugs In Development, 2024 Diabetic Macular Edema - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if left untreated. Risk factors include age and diabetes. The Diabetic Macular Edema drugs in development market...
-
Product Insights
Hyperlipidemia - Drugs In Development, 2024 Hyperlipidemia - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Hyperlipidemia – Drugs In Development, 2024 report and make more profitable business decisions. Hyperlipidemia is a medical condition characterized by elevated levels of lipids (fats) in the blood. This includes high levels of cholesterol and triglycerides. It is a significant risk factor for cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hyperlipidemia can be caused by genetic factors, an unhealthy diet high in saturated fats and cholesterol, sedentary lifestyle, obesity, and certain medical conditions...
-
Product Insights
Hypercholesterolemia - Drugs In Development, 2024 Hypercholesterolemia - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Hypercholesterolemia – Drugs In Development, 2024 report and make more profitable business decisions. Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads to the formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing a heart attack or stroke. Two forms of the condition exist: heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obesity, family...
-
Product Insights
Diabetic Foot Ulcers - Drugs In Development, 2024 Diabetic Foot Ulcers - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Foot Ulcers – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic foot ulcers are sores that occur on the feet of people with type 1 and type 2 diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg; pain; walking with difficulty; black, blue, or red discoloration of the feet; cold feet; and fever, skin redness, or swelling, or other signs of infection. The predisposing factors include diabetic...
-
Product Insights
Amyloidosis - Drugs In Development, 2024 Amyloidosis - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Amyloidosis – Drugs In Development, 2024 report and make more profitable business decisions. Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It can affect the shape and functioning of the affected organ, eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue,...
-
Product Insights
Diabetic Nephropathy - Drugs In Development, 2024 Diabetic Nephropathy - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Nephropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic nephropathy is damage to the kidney occurring due to diabetes. It is characterized by albuminuria, a reduction in glomerular filtration rate (GFR), and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels, and smoking. This condition is managed by medication and dietary modification. The Diabetic Nephropathy drugs in development market research report provide comprehensive information on the...
-
Product Insights
Diabetic Neuropathy - Drugs In Development, 2024 Diabetic Neuropathy - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Diabetic Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning, and pain. Predisposing factors include obesity, hypertension, high lipid and sugar levels, and smoking. It may be managed by medication and dietary modification. The Diabetic Neuropathy drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
Hypertriglyceridemia - Drugs In Development, 2024 Hypertriglyceridemia - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Hypertriglyceridemia – Drugs In Development, 2024 report and make more profitable business decisions. Hypertriglyceridemia is a condition in which the blood contains high levels of triglycerides, a type of fat that provides energy to the body. Triglycerides are important for normal metabolism, but excess amounts can increase the risk of cardiovascular diseases, such as atherosclerosis, coronary artery disease, and stroke. Hypertriglyceridemia can also cause acute pancreatitis, a serious inflammation of the pancreas that requires medical attention....
-
Product Insights
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Drugs In Development, 2024 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Drugs In Development, 2024
$2,000 | June 2024 Empower your strategies with our Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Drugs In Development, 2024 report and make more profitable business decisions. Familial hypercholesterolemia (FH) is a genetic disorder that affects the way the body processes cholesterol. People with FH have very high levels of low-density lipoprotein (LDL) cholesterol, also known as "bad" cholesterol, in their blood. This can lead to early and severe cardiovascular diseases, such as heart attacks and strokes. FH is caused by a mutation in one or...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.